

# Clinical Observation of Xeligekimab in the Treatment of Moderate to Severe Palmoplantar Pustulosis

NCT07503652

---

Status	RECRUITING
Phase	Phase 4
Sponsor	First Hospital of China Medical University
Enrollment	10 participants

## Key Eligibility Criteria

---

### Inclusion (3)

- Moderate to severe PPP: Baseline PPPASI score  $\geq 12$ , PPPIGA score  $\geq 3$  (moderate or severe).
- Dermatology Life Quality Index (DLQI) score  $\geq 10$ . Has received at least one local or systemic treatment (such as high-dose corticosteroids, methotrexate) in the past and the treatment was ineffective or intolerable.
- The patient or the patient's family signs the informed consent form. -

### Exclusion (4)

- Have used IL-17A inhibitors within the recent 3 months, or IL-23/TNF- $\alpha$  inhibitors within the past 4 months.
- Have severe comorbidities (such as ALT/AST  $> 3$  times the upper limit of normal, eGFR  $< 30$  mL/min/1.73 m<sup>2</sup>).
- Active infections (tuberculosis, hepatitis B, hepatitis C, HIV), pregnancy or lactation, drug allergies, participation in other clinical studies, etc.
- \-

## Locations (1 total)

---

First Hospital of China Medical University, Shenyang, China